WOBURN, Mass.--(BUSINESS WIRE)--Courtagen Life Sciences, Inc., a privately held life sciences company that provides innovative proteomic and genomic products and services to the life sciences industry, today announced that the company has submitted its first pre- IDE (Investigational Device Exemption) information package to the U.S. Food and Drug Administration for the Company’s Avantra® Q400 BioMarker Workstation and QPDX® BioChip for the measurement of C-reactive protein (CRP). Courtagen is also pursuing a CE Mark Approval for the European Union.
